Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $33 at Cantor Fitzgerald
-
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
KalVista Pharmaceuticals (KALV) Prices 5.375M Share Upsized Common Offering at $36/Sh
-
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
-
KalVista Pharmaceuticals (KALV) Announces 4.5M Share Proposed Public Offering of Common Stock
-
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Companies with NDRs 10/20
-
Companies with NDRs 10/19
-
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
-
Cantor Fitzgerald Starts Kalvista Pharmaceuticals Inc (KALV) at Overweight
-
KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares
-
KalVista Pharmaceuticals (KALV) Prices 4M Share Common Offering at $17/Sh
-
KalVista Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
KalVista Pharmaceuticals (KALV) Announces Proposed Common Share Offering
-
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock
